PMID- 32363940
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1532-7914 (Electronic)
IS  - 0163-5581 (Linking)
VI  - 73
IP  - 3
DP  - 2021
TI  - Oral Nutritional Supplementation in Cancer Patients Who Were Receiving 
      Chemo/Chemoradiation Therapy: A Multicenter, Randomized Phase II Study.
PG  - 442-449
LID - 10.1080/01635581.2020.1758170 [doi]
AB  - Introduction: Oral nutritional supplementation (ONS) in cancer patients is 
      justified by the low food intake caused by several factors. However, ONS can be 
      affected by adverse events (AEs) correlated to treatment. This study aimed to 
      compare the safety and efficacy of ONS (whey protein isolated, leucin, 
      zinc-IMMAX(R)) during oncologic treatment.Methods: Patients in 
      chemo/chemoradiotherapy were randomly assigned to receive IMMAX(R)+nutritional 
      counseling (NC) according to daily requirements (S arm) or NC alone (C arm) for 
      4 weeks. Body weight (BW), %fat-free mass (%FFM) and nutrition intake were 
      assessed before and after. In S arm, calories from IMMAX met the energy 
      requirements. AEs were classified according to CTC-AE-NCI.Results: Eighty-five 
      patients were included (51 females). After 4 weeks, the median of caloric intake, 
      BW and %FFM were not statistically different in C arm. In S arm, median ONS 
      intake was 81 g/332 kcal/day, protein intake was higher (pre: 66.75 +/- 31.57 g; 
      post: 88.57 +/- 35.11 g; p < 0.01) and calories as well (pre: 1,549 +/- 596 kcal; 
      post: 1,756 +/- 614 kcal; p = 0.02). The most common treatment related AEs were 
      anemia, nausea/vomiting, not different between the arms. AEs supplement related 
      were constipation and diarrhea (2 patients/4.6% each).Conclusion: IMMAX was safe, 
      well tolerated, it did not interfere with oncologic treatment and provided 
      significant amount of protein intake in this patient population, with few related 
      AEs.
FAU - Faccio, Adilson Aparecido
AU  - Faccio AA
AD  - Department of Oncology, IRPCC - Instituto Ribeiraopretano de Combate ao Cancer, 
      Ribeirao Preto, Brazil.
FAU - Mattos, Cecilia Helena Peinado de Sampaio
AU  - Mattos CHPS
AD  - Department of Nutrition, IRPCC - Instituto Ribeiraopretano de Combate ao Cancer, 
      Ribeirao Preto, Brazil.
FAU - Santos, Evandro Airton Sordi Dos
AU  - Santos EASD
AD  - Department of Oncology, IRPCC - Instituto Ribeiraopretano de Combate ao Cancer, 
      Ribeirao Preto, Brazil.
FAU - Neto, Natael Ribeiro Malta
AU  - Neto NRM
AD  - Department of Oncology, Santa Casa de Misericordia de Passos, Passos, Brazil.
FAU - Moreira, Raquel Pedro
AU  - Moreira RP
AD  - Department of Oncology, Santa Casa De Misericordia de Araraquara, Araraquara, 
      Brazil.
FAU - Luciara Tonelo Batella
AU  - Luciara Tonelo Batella
AD  - Instituto Ribeiraopretano de Combate ao Cancer, Ribeirao Preto, Brazil.
FAU - Santos, Hellin Dos
AU  - Santos HD
AD  - Prodiet Clinical Nutrition, Curitiba, Brazil.
FAU - Celes, Ana Paula Monnerat
AU  - Celes APM
AD  - Prodiet Clinical Nutrition, Curitiba, Brazil.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200502
PL  - United States
TA  - Nutr Cancer
JT  - Nutrition and cancer
JID - 7905040
SB  - IM
MH  - Chemoradiotherapy
MH  - Dietary Supplements
MH  - Energy Intake
MH  - Female
MH  - Humans
MH  - *Neoplasms/drug therapy
MH  - *Nutrition Therapy
EDAT- 2020/05/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1080/01635581.2020.1758170 [doi]
PST - ppublish
SO  - Nutr Cancer. 2021;73(3):442-449. doi: 10.1080/01635581.2020.1758170. Epub 2020 
      May 2.